Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Neoplasm Metastasis 1Melanoma 1Cutaneous Metastases 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × diphenylcyclopropenone × Dermatologic × Clear all
NCT05481658 2026-02-10

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting
100 enrolled
Dermatologic

Cutaneous Metastases

NCT01711684 2017-11-29

Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)

Rockefeller University

Phase 1 Completed
6 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡